NCT02343120

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 385 (actual)
• Sponsor: BeiGene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.

Conditions

• B-cell Malignancies

Interventions

Type	Name	Description
DRUG	Zanubrutinib	Oral administration by capsule

Timeline

• Start date: 2014-09-04
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2015-01-21
• Last updated: 2022-04-28
• Results posted: 2022-04-27

Locations

23 sites across 6 countries: United States, Australia, Italy, New Zealand, South Korea, United Kingdom

Regulatory

• FDA-regulated drug study